Our Pricing

Saxenda vs Wegovy for Prescription Weight Loss UK

When comparing saxenda vs wegovy uk options, understanding the clinical differences between these two prescription weight loss injections is essential for making an informed choice. Both are licensed by the MHRA for weight management in the UK, but they contain different active ingredients, require different dosing schedules, and deliver markedly different results in clinical trials.

Saxenda vs Wegovy UK: Key Differences Explained

Saxenda contains liraglutide, a once-daily injectable GLP-1 receptor agonist that has been available in the UK since 2015. Wegovy contains semaglutide, a once-weekly GLP-1 receptor agonist licensed more recently for chronic weight management [1]. The fundamental difference lies in their molecular structure: semaglutide has a longer half-life, allowing weekly rather than daily injections, and demonstrates significantly greater efficacy in head-to-head clinical comparisons.

In the STEP 8 trial, which directly compared semaglutide 2.4mg weekly against liraglutide 3mg daily, participants using semaglutide achieved an average 15.8% body weight reduction compared to 6.4% with liraglutide over 68 weeks [2]. This substantial difference in outcomes has made Wegovy the preferred first-line option for many UK prescribers when both treatments are clinically appropriate.

Beyond efficacy, the convenience factor matters considerably to patient adherence. Wegovy requires just one injection per week, whilst Saxenda demands daily injections, totalling 365 injections annually versus 52 with Wegovy. For busy patients managing work, family, and travel commitments, this difference often proves decisive in treatment selection and long-term compliance.

How Wegovy and Saxenda Work for Weight Loss

Both medications belong to the GLP-1 receptor agonist class, mimicking a natural gut hormone called glucagon-like peptide-1 that your body releases after eating. This hormone acts on multiple pathways: it slows gastric emptying so you feel fuller for longer, reduces appetite signals in the brain, and improves insulin sensitivity [1]. The net effect is reduced caloric intake without the conscious deprivation that makes traditional dieting unsustainable for many patients.

The critical distinction between saxenda vs wegovy uk treatments lies in their pharmacokinetic profiles. Semaglutide's extended half-life of approximately 7 days means stable blood levels throughout the week, providing consistent appetite suppression. Liraglutide's shorter half-life of 13 hours requires daily dosing to maintain therapeutic levels, and some patients report appetite returning towards the end of each 24-hour dosing interval [3].

Clinical trial data consistently demonstrates that semaglutide produces greater weight loss across all BMI categories and demographic groups. In the STEP 1 trial, 50.5% of participants on Wegovy achieved at least 15% body weight reduction, compared to historical Saxenda trial data showing approximately 25% of participants reaching this threshold [2][4]. These differences reflect semaglutide's more potent receptor binding and longer duration of action.

Mechanism of Action: What Happens in Your Body

When you inject Wegovy or Saxenda subcutaneously, the medication enters your bloodstream and binds to GLP-1 receptors located throughout your body, particularly in the pancreas, stomach, and appetite centres of the brain. This binding triggers a cascade of metabolic effects: insulin secretion increases in response to meals, glucagon secretion decreases, gastric motility slows, and hypothalamic appetite circuits receive satiety signals earlier and more strongly than usual [1].

The practical experience for most patients is a noticeable reduction in food-related thoughts, smaller portion sizes feeling satisfying, and diminished cravings for high-calorie foods. These effects typically emerge within the first 2-4 weeks of treatment and strengthen as doses are gradually increased to therapeutic levels under prescriber supervision.

Wegovy vs Saxenda: Clinical Trial Results and Real-World Efficacy

The STEP clinical trial programme for Wegovy enrolled over 4,500 participants across multiple studies, with the pivotal STEP 1 trial demonstrating an average 14.9% body weight reduction at 68 weeks compared to 2.4% with placebo [2]. Participants received weekly semaglutide 2.4mg alongside lifestyle intervention, with two-thirds achieving at least 10% weight loss and half reaching the 15% threshold associated with significant cardiometabolic benefits.

Saxenda's SCALE trial programme showed more modest results, with the SCALE Obesity and Prediabetes study reporting an average 8.0% weight loss at 56 weeks versus 2.6% with placebo [4]. Whilst this represents clinically meaningful weight reduction, the magnitude falls considerably short of what semaglutide achieves, making Wegovy the more effective option when comparing saxenda vs wegovy uk treatments for patients seeking maximum weight loss.

Real-world evidence from UK clinical practice mirrors these trial findings. At Cured Pharmacy, our clinical team observes that patients prescribed Wegovy typically report more substantial and sustained weight loss compared to historical Saxenda patients, alongside better treatment adherence due to the once-weekly dosing schedule. Superintendent pharmacist Tarun Kumar notes that patient satisfaction scores and continuation rates are consistently higher with semaglutide-based therapy when both options are clinically suitable.

Who Achieves Best Results with Each Treatment

Clinical predictors of success with GLP-1 therapy include starting BMI above 30 kg/m², absence of previous bariatric surgery, commitment to dietary modification, and tolerance of gastrointestinal side effects during dose escalation. Wegovy demonstrates superior efficacy across all patient subgroups, but the difference is particularly pronounced in patients with higher starting BMI and those seeking weight loss exceeding 15% [2][4].

Some UK prescribers reserve Saxenda for patients who specifically cannot manage weekly injections due to needle phobia or those who have previously succeeded on daily liraglutide for type 2 diabetes management. However, for most patients comparing these options, Wegovy represents the evidence-based first choice when clinically appropriate and accessible.

Side Effects: Saxenda vs Wegovy Safety Profiles

Both medications share a similar side effect profile dominated by gastrointestinal symptoms, reflecting their mechanism of slowing gastric emptying. Nausea affects approximately 44% of Wegovy users and 39% of Saxenda users during dose escalation, though symptoms typically diminish as the body adapts [1][4]. Other common effects include diarrhoea, constipation, vomiting, and abdominal discomfort, usually mild to moderate in severity.

The gradual dose escalation protocols built into both treatments help minimise these effects. Wegovy starts at 0.25mg weekly and increases monthly over 16-20 weeks to the maintenance dose of 2.4mg. Saxenda begins at 0.6mg daily and increases weekly to 3.0mg daily. This staged approach allows your digestive system to adapt progressively, though some patients still experience persistent nausea requiring dose reduction or treatment discontinuation [2][4].

Serious adverse events remain rare with both medications but require awareness. Pancreatitis occurs in less than 0.2% of patients, gallbladder disorders in approximately 1.5-2.5%, and there is a theoretical risk of thyroid C-cell tumours based on rodent studies, though no human cases have been causally linked to GLP-1 therapy [1][3]. Your UK prescriber will assess your personal risk factors during consultation, excluding patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Managing Side Effects During Treatment

Practical strategies significantly improve tolerability of GLP-1 medications. Eating smaller, more frequent meals rather than large portions, avoiding high-fat foods that delay gastric emptying further, staying well-hydrated, and injecting at consistent times help reduce nausea and digestive upset. If symptoms persist despite these measures, your prescriber may slow the dose escalation schedule or maintain you at a lower dose that balances efficacy with tolerability.

Most patients find side effects peak during the first 3-5 days after each dose increase, then gradually improve. Keeping a symptom diary helps identify patterns and triggers, enabling you and your clinical team to optimise your treatment plan. The Cured Pharmacy clinical team provides ongoing support throughout your treatment journey, with access to UK prescribers for dose adjustments and side effect management as needed.

Dosing and Administration: Weekly vs Daily Injections

Wegovy's once-weekly subcutaneous injection uses a pre-filled pen injected into the abdomen, thigh, or upper arm. The dose escalation schedule spans 16-20 weeks: 0.25mg weekly for 4 weeks, 0.5mg for 4 weeks, 1.0mg for 4 weeks, 1.7mg for 4 weeks, then 2.4mg as the maintenance dose [2]. Each pen contains a single dose, and injection takes approximately 10 seconds once you become familiar with the technique.

Saxenda requires daily subcutaneous injection at any time of day, though consistency helps with routine adherence. The escalation protocol increases by 0.6mg every week: starting at 0.6mg daily, then 1.2mg, 1.8mg, 2.4mg, reaching the 3.0mg maintenance dose by week 5 [4]. Each Saxenda pen contains multiple doses, requiring you to dial the correct amount before each injection, which some patients find more complex than Wegovy's single-dose pens.

From a practical adherence perspective, the difference between 52 and 365 injections annually proves significant in real-world use. UK patients often report that weekly Wegovy injections integrate more easily into their routines, particularly those who travel frequently for work or have irregular schedules. The reduced injection frequency also means fewer injection site reactions and less needle-related anxiety for patients with injection aversion.

Cost and Availability: Wegovy vs Saxenda Pricing UK

At Cured Pharmacy, Wegovy is available from £79.00 following online clinical assessment by a UK-registered prescriber. This transparent upfront pricing includes your medication, prescriber review, and discreet delivery to your UK address. All prescription weight loss treatments require clinical consultation to ensure safety and appropriateness, which our team completes in under 3 minutes through our streamlined online assessment.

When evaluating saxenda vs wegovy uk options, consider the total monthly injection burden alongside pricing. Wegovy's once-weekly dosing means 4 injections per month at maintenance dose, whilst Saxenda requires approximately 30 daily injections monthly. The convenience factor, combined with superior clinical efficacy demonstrated in head-to-head trials, makes Wegovy the preferred choice for most UK patients when both treatments are clinically suitable [2].

Supply availability fluctuates across the UK market due to high demand for GLP-1 weight loss medications. Cured Pharmacy maintains reliable stock of Wegovy through our established pharmaceutical supply chains, and our clinical team can advise on current availability during your consultation. As a UK-registered pharmacy (GPhC 9012511) under superintendent pharmacist Tarun Kumar (GPhC 2233073), we dispense only genuine UK-licensed medications with full regulatory compliance and patient safety oversight.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
2. Rubino, D. M., et al. (2022). Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA, 327(2), 138–150. https://doi.org/10.1001/jama.2021.23619
3. Lau, J., et al. (2015). Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry, 58(18), 7370–7380. https://doi.org/10.1021/acs.jmedchem.5b00726
4. Pi-Sunyer, X., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and cannot be guaranteed. Clinical trial data represents average outcomes and individual results may differ.